JP2025513714A5 - - Google Patents
Info
- Publication number
- JP2025513714A5 JP2025513714A5 JP2024556078A JP2024556078A JP2025513714A5 JP 2025513714 A5 JP2025513714 A5 JP 2025513714A5 JP 2024556078 A JP2024556078 A JP 2024556078A JP 2024556078 A JP2024556078 A JP 2024556078A JP 2025513714 A5 JP2025513714 A5 JP 2025513714A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22163663.2 | 2022-03-22 | ||
| EP22163663 | 2022-03-22 | ||
| PCT/EP2023/057248 WO2023180346A1 (en) | 2022-03-22 | 2023-03-21 | Deimmunized antibodies specific for cd3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513714A JP2025513714A (ja) | 2025-04-30 |
| JP2025513714A5 true JP2025513714A5 (enExample) | 2026-05-12 |
Family
ID=80930505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556078A Pending JP2025513714A (ja) | 2022-03-22 | 2023-03-21 | Ｃｄ３に特異的な脱免疫抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250206819A1 (enExample) |
| EP (1) | EP4496812A1 (enExample) |
| JP (1) | JP2025513714A (enExample) |
| KR (1) | KR20240158351A (enExample) |
| CN (1) | CN118922448A (enExample) |
| AU (1) | AU2023240297A1 (enExample) |
| CA (1) | CA3246381A1 (enExample) |
| IL (1) | IL315591A (enExample) |
| WO (1) | WO2023180346A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025087681A1 (en) | 2023-10-26 | 2025-05-01 | Morphosys Ag | Bispecific antibodies against cd3 and cd20 |
| WO2025106469A1 (en) * | 2023-11-14 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Engineered heavy chain variable domains and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| EP1990409A3 (en) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bacteriophage |
| AU2003236728A1 (en) | 2002-06-10 | 2003-12-22 | Algonomics N.V. | Method for predicting the binding affinity of mhc/peptide complexes |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| CA3051311A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| HRP20181811T1 (hr) | 2010-11-19 | 2018-12-28 | Morphosys Ag | Zbirka sljedova protutijela i njezina upotreba |
| DK2771364T3 (da) | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
| ES2742224T3 (es) * | 2013-11-07 | 2020-02-13 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos anti-WT1/HLA |
| RU2016151235A (ru) * | 2014-05-28 | 2018-06-28 | Ф. Хоффманн-Ля Рош Аг | Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус |
| US11472880B2 (en) * | 2017-08-14 | 2022-10-18 | Morphosys Ag | Humanized antibodies for CD3 |
| CA3121699A1 (en) | 2018-12-05 | 2020-06-11 | Morphosys Ag | Multispecific antigen-binding molecules |
-
2023
- 2023-03-21 CA CA3246381A patent/CA3246381A1/en active Pending
- 2023-03-21 EP EP23712893.9A patent/EP4496812A1/en active Pending
- 2023-03-21 CN CN202380029580.4A patent/CN118922448A/zh active Pending
- 2023-03-21 KR KR1020247034591A patent/KR20240158351A/ko active Pending
- 2023-03-21 WO PCT/EP2023/057248 patent/WO2023180346A1/en not_active Ceased
- 2023-03-21 AU AU2023240297A patent/AU2023240297A1/en active Pending
- 2023-03-21 JP JP2024556078A patent/JP2025513714A/ja active Pending
- 2023-03-21 IL IL315591A patent/IL315591A/en unknown
- 2023-03-21 US US18/847,483 patent/US20250206819A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522360A5 (enExample) | ||
| JP2022191383A5 (enExample) | ||
| JP2022079549A5 (enExample) | ||
| JP2023002562A5 (enExample) | ||
| JP2021526022A5 (enExample) | ||
| CN112135626A (zh) | 抗tigit抗体及其用途 | |
| RU2012112829A (ru) | Анти-gitr-антитела | |
| RU2020130795A (ru) | Нейтрализующие антитела к env вич-1 и их применение | |
| JP2024506315A5 (enExample) | ||
| JP2025067915A5 (enExample) | ||
| JP2019516348A (ja) | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 | |
| JP2023093753A5 (enExample) | ||
| JP2023540526A5 (enExample) | ||
| JP2020515277A5 (enExample) | ||
| JP2022540083A5 (enExample) | ||
| CN115605511A (zh) | 抗tigit的抗体、其制备方法和应用 | |
| JP2020518248A5 (enExample) | ||
| JP2026041756A5 (enExample) | ||
| CN110869390A (zh) | 抗pd-l1抗体及其用途 | |
| JP2023506834A5 (enExample) | ||
| JP2023542209A5 (enExample) | ||
| JP2024024114A5 (enExample) | ||
| JP2023506465A5 (enExample) | ||
| JP2023510982A5 (enExample) | ||
| JP2024540148A5 (enExample) |